A Smart Bomb for Ovarian Cancer: 92Bio's New Drug Enters Human Trials

HAYWARD, CA – July 01, 2026 – In a development that offers a new glimmer of hope for one of oncology’s most challenging diseases, 92Bio, Inc. announced it has dosed the first patient in a Phase 1 clinical trial for NTB-928, an investigational therapy for platinum-resistant ovarian cancer. While early-stage trials are just the first step on a long regulatory path, the science behind this new drug represents a sophisticated attempt to solve a problem that has long vexed cancer researchers: how to kill tumor cells without harming healthy tissue.

The trial, now underway at multiple U.S. sites, marks a pivotal moment for the Hayward-based biotech firm and, more importantly, for the community of patients and clinicians grappling with a diagnosis where the standard of care has offered only modest benefits. The drug, a T-cell engaging antibody, is designed not as a blunt instrument, but as a highly selective weapon, engineered to distinguish friend from foe on a molecular level.

The Unyielding Challenge of Resistant Cancer

To understand the significance of this trial, one must first understand the grim reality of platinum-resistant ovarian cancer (PROC). Ovarian cancer is often called a "silent killer" because its early symptoms are vague, leading to diagnosis at an advanced stage for a majority of women. The frontline treatment is typically a combination of surgery and platinum-based chemotherapy. While many patients initially respond, the cancer returns in approximately 80% of cases.

When it recurs within six months of completing platinum therapy, it is deemed "platinum-resistant." At this point, the prognosis darkens considerably. Median overall survival has historically hovered around a stark 12 to 18 months. Subsequent treatment options, such as single-agent chemotherapies, yield low response rates and offer only short-lived benefits. "Platinum-resistant ovarian cancer remains one of the most challenging settings in oncology," noted one leading expert not involved with the study, highlighting the "desperate need for novel therapeutic strategies." This is the landscape NTB-928 is stepping into—a field defined by profound unmet need.

A Promising Target with a Perilous Past

For years, scientists have had a promising target in their sights: a protein called folate receptor alpha, or FOLR1. This protein is an ideal marker, as it is heavily overexpressed on the surface of more than 75% of ovarian cancer cells while appearing only in trace amounts on a few types of normal tissues. In theory, a drug that targets FOLR1 could be a powerful tool against the disease.

However, theory has often clashed with clinical reality. The very presence of FOLR1 on healthy cells, even at low levels, creates a critical safety risk. Early attempts to target this protein with highly potent therapies ran into the problem of "on-target, off-tumor" toxicity, where the drug would attack not only the cancer but also healthy tissues in the lungs and kidneys, causing unacceptable side effects. This selectivity challenge has been a major barrier, constraining the development of some of the most powerful classes of immunotherapy for this disease.

Engineering a Smarter Weapon: The Science of NTB-928

92Bio believes its candidate, NTB-928, has the code to crack this problem. The drug is a bispecific T-cell engager (TCE), a class of immunotherapy that acts as a molecular matchmaker. One arm of the antibody is designed to grab onto a T-cell—the immune system's natural-born killer—while the other arm grabs onto a cancer cell. By physically linking the two, the TCE forces the T-cell to recognize and destroy the tumor.

The innovation lies in how NTB-928’s arms are engineered. The first, which binds to the CD3 protein on T-cells, is "affinity-tuned" to provide just enough of a signal to activate the T-cell without sending it into a hyper-inflammatory frenzy, a dangerous side effect known as cytokine release syndrome.

The second, and perhaps more critical, feature is its "avidity-dependent" FOLR1-binding arm. Instead of having one high-strength "hand" that can grab onto any FOLR1 it finds, this arm has two lower-strength "hands." For the drug to bind tightly, it needs to grab onto multiple FOLR1 proteins at once—a condition that only exists on cancer cells where the target is densely packed. On healthy cells with only sparse FOLR1, the grip is too weak to hold, and the T-cell is not engaged. Neither design feature alone is sufficient for selectivity; both are required to work in concert.

"NTB-928 was purpose-built to solve the selectivity challenge that has constrained FOLR1 targeted T-cell engagers in ovarian cancer," said Ben Buelow, MD, PhD, Chief Executive Officer of 92Bio. "Its unique combination of affinity-tuned CD3 engagement and avidity-dependent FOLR1 binding positions it specifically as a best-in-class candidate for patients with ovarian cancer."

A New Era in a Competitive Field

The initiation of this trial comes at a time of renewed momentum in ovarian cancer research. The field, once stagnant, has seen recent breakthroughs, most notably the 2022 approval of Elahere (mirvetuximab soravtansine), an antibody-drug conjugate (ADC) that also targets FOLR1. Unlike a TCE, an ADC acts like a Trojan horse, using the antibody to deliver a toxic chemotherapy payload directly into the cancer cell. Its success proved that targeting FOLR1 was a viable strategy and ushered in a new era of biomarker-driven therapy for the disease.

92Bio, a company founded in 2023 by a team with a track record of success from Teneobio (acquired by Amgen), is now testing a different, and potentially more powerful, approach by harnessing the patient's own immune system. The story of NTB-928 itself is one of persistence; the asset was originally developed by scientists now at 92Bio, passed to a larger pharmaceutical partner, and later returned to its creators, who are now advancing it under their new banner.

The Phase 1 trial, an open-label study designed to evaluate safety and determine the right dose, is the first test of this sophisticated engineering in humans. The first patient was dosed at START New York-Long Island, a site known for its work in early-phase cancer trials. "The initiation of this study represents an important step forward in evaluating a novel approach for patients with platinum-resistant ovarian cancer," said Dr. Geraldine O'Sullivan Coyne, the study's Principal Investigator at the site. "Milestones like this are only possible through a shared commitment to advancing research and expanding opportunities for patients.”

For the women and families affected by this devastating disease, every new trial represents a vital expansion of those opportunities. While the road ahead for NTB-928 is long and uncertain, the science it is built upon demonstrates a new level of sophistication in the systemic fight against cancer.